Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Purchased by Pflug Koory LLC

Pflug Koory LLC raised its position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 4.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,018 shares of the pharmaceutical company’s stock after acquiring an additional 79 shares during the quarter. Pflug Koory LLC’s holdings in Vertex Pharmaceuticals were worth $813,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of VRTX. State Street Corp grew its stake in Vertex Pharmaceuticals by 0.8% during the 3rd quarter. State Street Corp now owns 11,816,249 shares of the pharmaceutical company’s stock worth $5,495,501,000 after purchasing an additional 90,173 shares in the last quarter. Jennison Associates LLC grew its position in shares of Vertex Pharmaceuticals by 18.1% during the third quarter. Jennison Associates LLC now owns 5,550,386 shares of the pharmaceutical company’s stock worth $2,581,373,000 after buying an additional 851,054 shares in the last quarter. Wellington Management Group LLP increased its stake in shares of Vertex Pharmaceuticals by 17.2% during the third quarter. Wellington Management Group LLP now owns 4,798,870 shares of the pharmaceutical company’s stock worth $2,231,858,000 after buying an additional 704,421 shares during the period. Massachusetts Financial Services Co. MA raised its holdings in Vertex Pharmaceuticals by 5.8% in the third quarter. Massachusetts Financial Services Co. MA now owns 2,905,705 shares of the pharmaceutical company’s stock valued at $1,351,385,000 after acquiring an additional 159,693 shares in the last quarter. Finally, Janus Henderson Group PLC grew its holdings in Vertex Pharmaceuticals by 4.1% during the 3rd quarter. Janus Henderson Group PLC now owns 2,516,831 shares of the pharmaceutical company’s stock worth $1,170,506,000 after acquiring an additional 100,114 shares in the last quarter. 90.96% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on VRTX. BMO Capital Markets decreased their price objective on shares of Vertex Pharmaceuticals from $566.00 to $520.00 and set an “outperform” rating for the company in a research report on Friday, December 20th. Scotiabank upped their price objective on Vertex Pharmaceuticals from $426.00 to $430.00 and gave the stock a “sector perform” rating in a research report on Monday, December 23rd. Stifel Nicolaus raised their target price on Vertex Pharmaceuticals from $490.00 to $494.00 and gave the stock a “hold” rating in a research report on Monday, December 16th. Wells Fargo & Company lowered their price target on Vertex Pharmaceuticals from $555.00 to $460.00 and set an “overweight” rating for the company in a report on Friday, January 10th. Finally, Oppenheimer cut shares of Vertex Pharmaceuticals from an “outperform” rating to a “market perform” rating in a report on Thursday, December 19th. Two research analysts have rated the stock with a sell rating, ten have given a hold rating, eighteen have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $494.84.

Vertex Pharmaceuticals Trading Down 0.0 %

Vertex Pharmaceuticals stock opened at $439.62 on Friday. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.47 and a quick ratio of 2.20. Vertex Pharmaceuticals Incorporated has a one year low of $377.85 and a one year high of $519.88. The business has a fifty day moving average of $435.88 and a two-hundred day moving average of $464.95.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its quarterly earnings data on Monday, November 4th. The pharmaceutical company reported $4.38 EPS for the quarter, topping analysts’ consensus estimates of $3.61 by $0.77. Vertex Pharmaceuticals had a negative net margin of 4.52% and a negative return on equity of 1.91%. The firm had revenue of $2.77 billion for the quarter, compared to the consensus estimate of $2.69 billion. During the same quarter in the previous year, the firm earned $3.67 earnings per share. The firm’s revenue was up 11.6% on a year-over-year basis. Research analysts forecast that Vertex Pharmaceuticals Incorporated will post -1.9 EPS for the current fiscal year.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.